OTR3 has a strong pipeline that
relies on the considerable potential
of the RGTA® technology
OTR3 focuses on high potential programs
including some award winning key projects.
OTR3 focuses on key development projects with high potential, with the aim of exploiting the versatility of the RGTA® technology to provide to patients new healthcare products that really matter.
The following development programs, relying on the regenerating potential of RGTA® molecules, are just only a fraction of the technology’s potential, and are to date the closer to market.
The excellence and potential of OTR3’s Pipeline has been confirmed by awards and grants (H2020 SME Instrument, Medicen Label, ANR grant)
Ischemic stroke
RGTA® treatment aims at improving functional recovery by neuronal protection
Alzheimer Disease
Helping patients by blocking Tau protein propagation and protecting neuronal environment
Oral Mucositis
RGTA® should represent a new solution for patient to heal ulcerations and reduce pain
Tendonitis
(horse)
Clinical Trial (RCT) showed that RGTA® improves tendon healing and results in faster recovery
Tendonitis
RGTA® could bring to a potential treatment to allow better patient recovery by tendon regeneration
Epidermolysis bullosa
A new therapeutic solution for skin wound healing and associated pain reduction
